Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients?
The concurrent use of calcitriol (CAL) pulse therapy to reduce parathyroid hormone (PTH) secretion and of calcium (Ca) salts as the most appropriate phosphate binders was evaluated for over 1 year in a group of 14 patients with good divalent ion control on CaCO3 therapy but with increasing levels of serum intact PTH. CAL pulse therapy was effective and safe in only 2 patients; in the remaining subjects it resulted in hypercalcemia and/or hyperphosphatemia, not reversed by adjusting the dialysate Ca concentration and or CaCO3 dose, and had to be stopped. Therefore, CAL pulse therapy does not seem to be compatible with Ca salts which, in our opinion, deserve priority in the therapy of renal dialysis patients.
Gonella
M
M
Renal Unit, General Hospital, Casale Monferrato, Italy.
Calabrese
G
G
Aleo
A G
AG
Vagelli
G
G
Deambrogio
P
P
D000469:Alkaline Phosphatase / Q000097:blood; D001806:Blood Urea Nitrogen; D002117:Calcitriol / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D017583:Hemodiafiltration / Q000009:adverse effects*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000209:etiology; D008274:Magnesium / Q000097:blood; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood* / Q000378:metabolism; D010710:Phosphates / Q000097:blood; D013997:Time Factors
D006454:Hemoglobins; D010281:Parathyroid Hormone; D010710:Phosphates; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002119:Calcium Carbonate; D008274:Magnesium; D002118:Calcium